The US Food and Drug Administration (FDA) has approved Sanofi and Regeneron Pharmaceuticals’ drug Dupixent for use in treating chronic spontaneous urticaria (CSU), a skin disorder caused by an overreactive immune response. This approval signals a new method of treating CSU for patients aged 12 and up who haven’t responded to antihistamines. Dupixent’s approval was based on successful phase 3 trials.
M&S issues update as crippling nationwide IT outage still ongoing – The Sun
Marks & Spencer (M&S) halted online orders in the UK and Ireland following a cyber attack, leading to a 5% drop in share price. Physical
